// App-Quantinova.ai

AB0523 (2021) : LONG-TERM SAFETY AND EFFECTIVENESS OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS AT 56 WEEKS FROM THE SELECT-PsA 1 STUDY

Researchers

Presenter

  • I. McInnes

Principal Investigators

  • K. Kato

  • M. Magrey

  • J. F. Merola

  • M. Kishimoto

  • C. F. Pacheco Tena

  • L. Chen

  • Y. Duan

  • P. Zueger

  • J. Liu

  • R. Lippe

  • A. Pangan

  • F. Behrens

Medical Centers

  • University of Glasgow, Medical Veterinary and Life Sciences, Glasgow, United Kingdom

  • AbbVie Inc, Immunology, Illinois, United States of America

  • MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, United States of America

  • Harvard Medical School, Division of Rheumatology and Clinical Immunology, Boston, United States of America

  • Brigham and Women’s Hospital, Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Boston, United States of America

  • Kyorin University School of Medicine, Department of Nephrology and Rheumatology, Mitaka, Japan

  • Universidad Autonoma de Chihuahua, Facultad de Medicina, Chihuahua, Mexico

  • Waterside Clinic, Barrie, ON, Canada

  • AbbVie Deutschland GmbH & Co. KG, Immunology, Berlin, Germany

  • Goethe University & Fraunhofer IME-TMP and CIMD, Frankfurt, Germany

Locations

  • United Kingdom

  • United States

  • Japan

  • Mexico

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved